CGCABLE
834639
KLT
831689
DAYU BIOLOGICAL
871970
4
Fujian Superpipe
300198
5
WuHan Hvsen Biotechnology
300871
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Current assets | ||||||||||
Money funds | 84.79%449.94M | 39.22%335.87M | 141.98%483.05M | 32.64%372.05M | 8.54%243.48M | 119.00%241.25M | 187.14%199.63M | 30.74%280.49M | 27.36%224.32M | 441.81%110.16M |
Transactional financial assets | -16.66%50.02M | 74.68%140.33M | -45.47%60.01M | -33.25%60.31M | -55.56%60.02M | -65.31%80.34M | -52.42%110.05M | -25.38%90.35M | -35.75%135.06M | 155,541.41%231.59M |
Notes receivable and accounts receivable | 4.75%201.1M | 21.96%196.62M | 23.32%182.79M | 37.52%179.28M | 26.35%191.98M | -23.38%161.21M | -31.82%148.22M | -45.31%130.36M | -33.15%151.94M | -4.24%210.41M |
-Notes receivable | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -61.05%6.43M | -38.60%11.3M |
-Accounts receivable | 4.75%201.1M | 21.96%196.62M | 23.32%182.79M | 37.52%179.28M | 31.93%191.98M | -19.04%161.21M | -27.58%148.22M | -42.21%130.36M | -30.96%145.51M | -1.10%199.12M |
Other receivables (including interest and dividends) | -54.10%2.58M | -8.82%2.98M | 18.48%3.63M | -34.25%2.81M | 188.97%5.62M | 71.81%3.27M | 19.82%3.06M | 122.85%4.28M | -17.65%1.94M | -22.48%1.9M |
-Other receivable | ---- | -8.82%2.98M | ---- | ---- | ---- | 71.81%3.27M | ---- | 122.85%4.28M | ---- | -22.48%1.9M |
Advance payment | -2.31%5.35M | -50.49%2.39M | 480.93%12.39M | 152.90%6.11M | 54.76%5.47M | -46.22%4.82M | -70.52%2.13M | -36.11%2.42M | -51.46%3.54M | 91.01%8.96M |
Inventories | 39.92%120.37M | 51.24%111.86M | 24.43%88.63M | -3.67%72.09M | 19.85%86.03M | -28.74%73.96M | -45.33%71.23M | -37.11%74.84M | -42.51%71.78M | -7.70%103.8M |
Receivable financing | -88.91%855.32K | -78.64%3.44M | -67.85%3.48M | 38.24%8.58M | 345.19%7.72M | 10,168.76%16.13M | 431.31%10.84M | 4,351.41%6.21M | 246.61%1.73M | -93.58%157.05K |
Non-current assets due within one year | ---- | 156.48%109.74M | 988.76%108.88M | 1,313.91%141.39M | --150.23M | --42.79M | --10M | --10M | ---- | ---- |
Other current assets | 181.48%9.88M | 123.48%6.17M | -37.79%3.9M | -57.16%3.35M | 105.45%3.51M | 174.13%2.76M | 213.10%6.26M | 213.56%7.82M | -31.36%1.71M | -86.24%1.01M |
Total current assets | 11.41%840.09M | 45.15%909.4M | 68.63%946.75M | 39.42%845.97M | 27.37%754.06M | -6.21%626.52M | -15.24%561.42M | -13.48%606.77M | -21.18%592.03M | 80.75%668M |
Non Current assets | ||||||||||
Other debt investment | 691.20%80.92M | -91.03%10.46M | -93.00%10.38M | -91.08%10.31M | -91.79%10.23M | 2.73%116.68M | 31.62%148.24M | 3.40%115.49M | --124.54M | --113.57M |
Other non-current financial assets | 0.00%20M | 0.00%20M | 0.00%20M | 0.00%20M | 0.00%20M | 0.00%20M | --20M | --20M | --20M | --20M |
Fixed assets | ---- | 8.19%250.2M | ---- | ---- | ---- | -2.52%231.27M | ---- | 11.25%236.26M | ---- | 11.46%237.24M |
Constru in process | ---- | 41.83%42.09M | ---- | ---- | ---- | 96.60%29.68M | ---- | -74.91%10.51M | ---- | 133.42%15.1M |
Productive biological assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
Oil and gas assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
Intangible assets | 38.51%27.05M | 242.87%27.25M | 242.33%27.46M | 139.65%19.39M | 139.12%19.53M | -3.54%7.95M | -3.50%8.02M | -3.47%8.09M | -3.44%8.17M | -3.41%8.24M |
Development expenditure | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
Goodwill | 0.00%3.98M | 0.00%3.98M | 0.00%3.98M | 0.00%3.98M | 0.00%3.98M | 0.00%3.98M | 0.00%3.98M | 0.00%3.98M | --3.98M | --3.98M |
Long deferred expense | 80.05%4.73M | -4.58%1.4M | -7.25%1.76M | -9.17%2.16M | -28.15%2.63M | -62.45%1.46M | -56.79%1.89M | -35.39%2.38M | -1.13%3.65M | 10.18%3.9M |
Deferred tax assets | -22.72%5.15M | -21.02%5.31M | 15.63%5.16M | 36.11%5.72M | 186.56%6.67M | 140.77%6.72M | 42.35%4.46M | 38.54%4.21M | -30.44%2.33M | -15.96%2.79M |
Usufruct assets | -45.17%5.81M | -40.71%6.97M | 28.18%8.13M | 25.69%9.29M | 199.37%10.6M | 179.67%11.76M | 30.31%6.34M | 33.62%7.39M | 0.51%3.54M | 0.35%4.2M |
Other non current assets | 1,135.31%22.16M | 82.52%3.68M | 35.79%2.76M | -90.90%1.4M | -7.10%1.79M | -19.32%2.02M | -19.94%2.03M | 413.72%15.34M | -20.09%1.93M | -34.95%2.5M |
Total non current assets | 53.72%517.98M | -13.94%371.35M | -23.94%346.76M | -20.16%338.26M | -19.96%336.97M | 4.86%431.52M | 16.23%455.88M | 7.64%423.65M | 55.61%421.03M | 69.54%411.53M |
Total assets | 24.48%1.36B | 21.05%1.28B | 27.15%1.29B | 14.93%1.18B | 7.70%1.09B | -1.99%1.06B | -3.53%1.02B | -5.89%1.03B | -0.85%1.01B | 76.30%1.08B |
Liabilities | ||||||||||
Current liabilities | ||||||||||
Short term loan | 25.39%50.16M | -33.29%30.02M | 60.00%40M | 2.59%40.03M | 13.47%40M | -38.38%45M | -58.65%25M | -24.28%39.02M | -34.99%35.25M | 19.87%73.03M |
Transactional financial liabilities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --1.6M | --884.11K |
Notes payable and accounts payable | 3.40%151.68M | 26.59%150.28M | 34.16%150.22M | 32.73%133.53M | 59.78%146.7M | -1.05%118.71M | -8.14%111.97M | -40.02%100.6M | -29.78%91.81M | 16.97%119.96M |
-Notes payable | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --25M | ---- |
-Accounts payable | 3.40%151.68M | 26.59%150.28M | 34.16%150.22M | 32.73%133.53M | 119.57%146.7M | -1.05%118.71M | -8.14%111.97M | -40.02%100.6M | -48.90%66.81M | 16.97%119.96M |
Contract liabilities | -68.25%269.06K | -59.94%156.67K | 147.34%437.85K | -73.26%168.38K | 199.21%847.48K | -47.12%391.05K | -68.91%177.02K | 62.38%629.61K | -15.42%283.24K | 75.06%739.48K |
Salaries payable | 7.04%9.92M | 18.90%10.11M | 16.48%9.19M | -37.34%10.99M | 51.80%9.27M | 17.01%8.5M | -9.91%7.89M | -34.38%17.53M | -47.72%6.1M | -28.67%7.26M |
Taxs payable | 88.78%3.39M | 58.82%1.35M | 691.10%1.32M | -75.47%880.7K | 689.61%1.79M | -77.44%847.23K | -91.95%167K | 34.32%3.59M | -91.22%227.15K | -36.41%3.76M |
Other payable (including interest and dividends) | 19.73%5.03M | 32.23%5.47M | 38.58%4.58M | 34.70%4.69M | -20.03%4.2M | -12.79%4.14M | -49.31%3.31M | -69.51%3.48M | -10.70%5.25M | 25.82%4.74M |
-Other payable | ---- | 32.23%5.47M | ---- | ---- | ---- | -12.79%4.14M | ---- | -69.51%3.48M | ---- | 25.82%4.74M |
Non current liabilities due within one year | 8.88%4.79M | 6.61%4.75M | 20.13%4.71M | 6.06%4.62M | 56.50%4.4M | 60.78%4.45M | 37.97%3.92M | 62.79%4.36M | --2.81M | 4.45%2.77M |
Other current liabilities | -82.38%16.05K | -93.73%1.98K | -76.46%38.61K | -93.86%3.81K | 147.37%91.08K | -67.09%31.63K | 121.53%164K | -21.31%62K | -15.42%36.82K | 74.20%96.13K |
Total current liabilities | 8.66%225.25M | 11.02%202.12M | 37.94%210.49M | 15.15%194.91M | 44.58%207.3M | -14.62%182.07M | -24.90%152.59M | -35.69%169.28M | -30.23%143.38M | 14.36%213.25M |
Current liabilities | ||||||||||
Long term loan | --51.44M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Deferred tax liabilities | -64.43%1.39M | -35.18%2.59M | 14.51%2.65M | 41.06%3.33M | 725.27%3.9M | 559.26%4M | 320.64%2.32M | 522.08%2.36M | --472.84K | --606.86K |
Lease liabilities | -78.89%1.36M | -65.63%2.57M | 41.98%3.76M | 52.16%4.97M | 562.24%6.44M | 341.76%7.47M | 15.65%2.65M | 5.42%3.27M | -73.29%972.94K | 4.12%1.69M |
Total non current liabilities | 423.74%54.18M | -55.01%5.16M | 29.17%6.42M | 47.51%8.3M | 615.56%10.35M | 399.17%11.48M | 74.75%4.97M | 61.69%5.63M | -60.31%1.45M | 41.46%2.3M |
Total liabilities | 28.39%279.43M | 7.10%207.29M | 37.67%216.91M | 16.19%203.21M | 50.28%217.64M | -10.21%193.54M | -23.53%157.56M | -34.42%174.9M | -30.75%144.82M | 14.59%215.54M |
Shareholders equity | ||||||||||
Paid-in capital | 6.94%110.32M | 6.94%110.32M | 6.94%110.32M | 6.94%110.32M | 0.00%103.15M | 0.00%103.15M | 0.00%103.15M | 0.00%103.15M | 0.00%103.15M | 33.34%103.15M |
Capital reserve funds | 28.77%486.34M | 29.14%485.42M | 29.52%484.5M | 29.27%483.58M | 0.96%377.67M | 0.48%375.88M | 0.00%374.08M | 0.00%374.08M | 0.00%374.08M | 887.89%374.08M |
Surplus reserve funds | 3.54%38.25M | 3.54%38.25M | 3.54%38.25M | 3.54%38.25M | 7.28%36.94M | 7.28%36.94M | 7.28%36.94M | 7.28%36.94M | 34.31%34.43M | 34.31%34.43M |
Retained profit | -0.01%355.6M | 0.62%350.7M | 2.45%354.03M | 2.21%348.88M | -0.26%355.63M | -1.07%348.53M | 2.59%345.57M | 7.83%341.35M | 15.13%356.57M | 24.34%352.32M |
Less:Treasury stock | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
Other composite income | 144.72%427.45 | 3.63%-1.28K | -153.28%-927.65 | -118.73%-715.35 | -196.24%-955.84 | -195.95%-1.33K | 35.12%-366.25 | 39.93%-327.05 | 33.95%-322.66 | 8.85%-447.89 |
Specific reserves | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
Shareholders equity without minority interests | 13.41%990.51M | 13.90%984.69M | 14.81%987.09M | 14.67%981.02M | 0.59%873.39M | 0.06%864.5M | 1.32%859.75M | 3.30%855.52M | 6.85%868.24M | 103.67%863.98M |
Minority interests | --88.13M | --88.78M | --89.51M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Total shareholder equity | 23.50%1.08B | 24.17%1.07B | 25.22%1.08B | 14.67%981.02M | 0.59%873.39M | 0.06%864.5M | 1.32%859.75M | 3.30%855.52M | 6.85%868.24M | 103.67%863.98M |
Total liabilityies and equity | 24.48%1.36B | 21.05%1.28B | 27.15%1.29B | 14.93%1.18B | 7.70%1.09B | -1.99%1.06B | -3.53%1.02B | -5.89%1.03B | -0.85%1.01B | 76.30%1.08B |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
Auditor | -- | -- | -- | Beijing Dahua International Accounting Firm (Special General Partnership) | -- | -- | -- | Dahua Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.